Asian Investors Bankroll €40m Promethera Biosciences Series D

 
• By Mike Ward

Liver disease-focused Belgian cell therapy biotech Promethera Biosciences closes a €39.7m ($44.4m) Series D round co-led by new Japanese investors Itochu Corporation and Shinsei Capital Partners. Asian investors now own about 44% of company.

liver
Promethera Uses Cell Therapy Approach To Treat Liver Diseases • Source: Shutterstock

More from Business

More from Scrip